fr   en
Agreement

Tableaux synoptiques (en anglais)


Parcourir par date
Rechercher par mot clé
Date: 2006-02-08
Biotech partner: G2Therapies (Australia)
Pharma Partner: Novo Nordisk (Denmark)
Type of agreement: * R&D
* manufacturing
* commercialization/ distribution
Compound: anti-inflammatories based on anti-C5a receptor antibodies
Disease area: rheumatoid arthritis and other auto-immune diseases
Development phase:  
Nature of the agreement:  
Financial terms of the agreement: initial payment of $6 million and up to $102 million in milestone payments


Go back to previous page